ESMO 2018: Industry Participation

ESMO 2018, the world's premier congress in medical oncology will be taking place in Munich from the 19 - 23 October 2018.

The congress will attract an international community of experts, across disciplines and all focused on finding the most effective cancer treatment solutions available today.This is the ultimate goal of ESMO 2018 and we count on our Industry Partners active in oncology to help us again further our science and improve the lives of patients through continued education.

Fast Facts: ESMO 2017 Congress

  • 23916 participants, 131 countries
  • 7014 m² exhibition space, 167 exhibitors
  • 550 invited speakers
  • 191 sessions, 21 tracks 
  • 3260 submitted abstracts

How can I participate in 2018?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate your presence at our congress.

Contact the  ESMO Events Sponsorship Team  for more details and we look forward to hearing from you!

Who has already signed up?

We gratefully acknowledge the valuable contribution of the following organisations in the ESMO 2018 Congress through their presence in the exhibition hall, organisation of sponsored sessions, or via sponsorship activities (as of April 2018)

Companies
  • AbbVie, Inc.
  • Advanced Accelerator Applications
  • Advanced Targeting Systems
  • Almac Diagnostics
  • Amgen (Europe) GmbH
  • Amoy Diagnostics Co., Ltd.
  • ArcherDX
  • Astellas Pharma Europe Ltd.
  • AstraZeneca
  • Bavarian Nordic
  • Bayer
  • BeiGene, Ltd.
  • Biocartis
  • Biopticon 
  • BMJ
  • Boehringer Ingelheim 
  • Braster 
  • Bristol-Myers Squibb
  • Calithera Biosciences
  • Cancers MDPI
  • Cascadian Therapeutics, Inc.
  • Catalysis S.L.
  • Celgene
  • Celldex Therapeutics
  • Celltrion Healthcare Co., Ltd.
  • Cepheid
  • Clinical Research Malaysia (CRM)
  • Clovis Oncology
  • Covance/Chiltern
  • Covaris
  • Daiichi-Sankyo
  • Definiens
  • Delcath Systems
  • Dr. Reddys Laboratories
  • Eisai Europe Ltd.
  • Elsevier B.V.
  • EMJ - European Medical Journal
  • Eurofins Clincial Diagnostics
  • Europital
  • EUSA Pharma (UK) Ltd.
  • F.Hoffmann-La Roche 
  • Fresenius Kabi
  • Genmab
  • Genomic Health International Sarl
  • Gilead Sciences Inc.
  • GSK
  • HalioDx
  • Helsinn Healthcare SA
  • HUMEDIQ global GmbH
  • Imedex, an HMP Company
  • Immunomedics
  • Incyte Biosciences International Sarl
  • Invivoscribe
  • Ipsen
  • ITM Isotopen Technologien Muenchen AG
  • Janssen
  • Karger Publishers
  • LeCancer.fr
  • Lilly
  • Loxo Oncology, Inc.
  • MacroGenics, Inc
  • medac GmbH
  • Median Technologies
  • Medscape Oncology
  • Merck 
  • Molecular Health GmbH
  • MSD
  • Mylan
  • NanoString Technologies 
  • NEJM Group 
  • Noona Healthcare Oy
  • Novartis Oncology
  • Novella Clinical, a Quintiles company
  • Nutricia Advanced Medical Nutrition
  • OncLive
  • Oncology Central
  • Oxford University Press
  • Paxman
  • PER Global, LLC
  • Personal Genome Diagnostics
  • Pfizer Biosimilars
  • Pfizer Oncology
  • Pharma Mar
  • Pharmadab d.o.o.
  • Phillips Molecular
  • Pierre Fabre Oncology
  • Pivotal
  • Precision Oncology
  • Predicine
  • prIME Oncology
  • Samsung Bioepis Co., Ltd.
  • Sandoz, a Novartis Company
  • Sanofi Genzyme
  • Seattle Genetics
  • Servier
  • Shire
  • Sophia Genetics
  • Sotio a.s.
  • Springer Healthcare
  • Sysmex Inostics GmbH/Sysmex Europe GmbH
  • Takeda Oncology
  • Tesaro
  • The JAMA Network
  • Thermo Fisher Scientific